Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors

Jacqueline Vuky; John McCaffrey; Michelle Ginsberg; Tania Mariani; Dean F. Bajorin; George J. Bosl; Robert J. Motzer

doi:10.1023/A:1006434008357

Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors

Jacqueline Vuky, John McCaffrey, Michelle Ginsberg, Tania Mariani, Dean F. Bajorin, George J. Bosl, Robert J. Motzer

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Thirteen patients with cisplatin-refractory germ cell tumors were treated on a Phase II trial with pyrazoloacridine. Pyrazoloacridine was given intravenously at 600 mg/m² every three weeks. The median nadir leucocyte count was 2.5 cells/mm³, hemoglobin was 10.8 g/dl, and platelet count was 126, 000 cells/m³. None of the thirteen evaluable patients achieved a major response. Pyrazoloacridine is not efficacious in the treatment of cisplatin-refractory germ cell tumours.

Original language	English (US)
Pages (from-to)	265-267
Number of pages	3
Journal	Investigational New Drugs
Volume	18
Issue number	3
DOIs	https://doi.org/10.1023/A:1006434008357
State	Published - 2000
Externally published	Yes

Keywords

Cisplatin-refractory
Germ cell tumor
Pyrazoloacridine

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

Access to Document

10.1023/A:1006434008357

Cite this

@article{d9c3eb90449a4467bfc8ac6950b3b514,

title = "Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors",

abstract = "Thirteen patients with cisplatin-refractory germ cell tumors were treated on a Phase II trial with pyrazoloacridine. Pyrazoloacridine was given intravenously at 600 mg/m2 every three weeks. The median nadir leucocyte count was 2.5 cells/mm3, hemoglobin was 10.8 g/dl, and platelet count was 126, 000 cells/m3. None of the thirteen evaluable patients achieved a major response. Pyrazoloacridine is not efficacious in the treatment of cisplatin-refractory germ cell tumours.",

keywords = "Cisplatin-refractory, Germ cell tumor, Pyrazoloacridine",

author = "Jacqueline Vuky and John McCaffrey and Michelle Ginsberg and Tania Mariani and Bajorin, {Dean F.} and Bosl, {George J.} and Motzer, {Robert J.}",

year = "2000",

doi = "10.1023/A:1006434008357",

language = "English (US)",

volume = "18",

pages = "265--267",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "3",

}

TY - JOUR

T1 - Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors

AU - Vuky, Jacqueline

AU - McCaffrey, John

AU - Ginsberg, Michelle

AU - Mariani, Tania

AU - Bajorin, Dean F.

AU - Bosl, George J.

AU - Motzer, Robert J.

PY - 2000

Y1 - 2000

N2 - Thirteen patients with cisplatin-refractory germ cell tumors were treated on a Phase II trial with pyrazoloacridine. Pyrazoloacridine was given intravenously at 600 mg/m2 every three weeks. The median nadir leucocyte count was 2.5 cells/mm3, hemoglobin was 10.8 g/dl, and platelet count was 126, 000 cells/m3. None of the thirteen evaluable patients achieved a major response. Pyrazoloacridine is not efficacious in the treatment of cisplatin-refractory germ cell tumours.

AB - Thirteen patients with cisplatin-refractory germ cell tumors were treated on a Phase II trial with pyrazoloacridine. Pyrazoloacridine was given intravenously at 600 mg/m2 every three weeks. The median nadir leucocyte count was 2.5 cells/mm3, hemoglobin was 10.8 g/dl, and platelet count was 126, 000 cells/m3. None of the thirteen evaluable patients achieved a major response. Pyrazoloacridine is not efficacious in the treatment of cisplatin-refractory germ cell tumours.

KW - Cisplatin-refractory

KW - Germ cell tumor

KW - Pyrazoloacridine

UR - http://www.scopus.com/inward/record.url?scp=0033894907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033894907&partnerID=8YFLogxK

U2 - 10.1023/A:1006434008357

DO - 10.1023/A:1006434008357

M3 - Article

C2 - 10958596

AN - SCOPUS:0033894907

SN - 0167-6997

VL - 18

SP - 265

EP - 267

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 3

ER -

Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this